Skip to main content

Advertisement

Log in

SHP-1 Protein Tyrosine Phosphatase Affects Early Postnatal Bone Development in Mice

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

The Src homology region 2 domain-containing phosphatase-1 (SHP-1) is an intracellular tyrosine phosphatase that plays a negative regulatory role in immune cell signaling. Absent or diminished SHP-1 catalytic activity results in reduced bone mass with enhanced bone resorption. Here, we sought to investigate if Shp1 overexpression leads to increased bone mass and improved mechanical properties. Male and female wildtype (WT) and SHP1-transgenic (Tg) mice at 28, 56, and 84 days of age were compared. We applied microcomputed tomography to assess femoral cortical bone geometry and trabecular architecture and 3-point mechanical bending to assess mid-diaphyseal structural and estimated material properties. Serum OPG, RANKL, P1NP, and CTX-1 concentrations were measured by enzyme-linked immunoassay. The majority of transgene effects were restricted to the 28-day-old mice. Trabecular bone volume per total volume, trabecular number, and connectivity density were greater in 28-day-old female SHP1-Tg mice when compared to WTs. SHP1-Tg female mice showed increased total and medullary areas, with no difference in cortical area and thickness. Cortical tissue mineral density was strongly genotype-dependent. Failure load, yield load, ultimate stress, and yield stress were all lower in 28-day-old SHP1-Tg females. In 28-day-old SHP1-Tg females, circulating levels of OPG and P1NP were higher and RANKL levels were lower than WT controls. Our study demonstrates a role for SHP-1 in early postnatal bone development; SHP-1 overexpression negatively impacted whole bone strength and material properties in females.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

SHP-1:

Src homology region 2 domain-containing phosphatase-1

SHP1-Tg:

SHP-1 transgenic

µCT:

Micro-computed tomography

BV/TV:

Bone volume per total volume

P1NP:

Procollagen type 1 N-terminal propeptide

CTX-1:

C-terminal telopeptide

OPG:

Osteoprotegerin

RANKL:

Receptor activator of nuclear factor kappa-B ligand

WT:

Wildtype

RANK/TRAF6:

Receptor activator nuclear factor kappa-B/TNF receptor-associated factor 6

NFĸb:

Nuclear factor kappa-B

MSC:

Mesenchymal stem cell

SIBLING:

Small integrin binding ligand, N-linked glycoprotein

MEPE:

Matrix extracellular phosphoglycoprotein

HRP:

Horseradish peroxidase

ANOVA:

Analysis of variance

References

  1. Neel BG, Tonks NK (1997) Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 9(2):193–204

    Article  CAS  PubMed  Google Scholar 

  2. Nesterovitch AB et al (2011) Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol 178(4):1434–1441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Nesterovitch AB et al (2011) Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans. Am J Pathol 178(4):1701–1714

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Aoki K et al (1999) The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice. Bone 25(3):261–267

    Article  CAS  PubMed  Google Scholar 

  5. Granot-Attas S, Elson A (2008) Protein tyrosine phosphatases in osteoclast differentiation, adhesion, and bone resorption. Eur J Cell Biol 87(8–9):479–490

    Article  CAS  PubMed  Google Scholar 

  6. Umeda S et al (1999) Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. Am J Pathol 155(1):223–233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhang Z, Jimi E, Bothwell AL (2003) Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. J Immunol 171(7):3620–3626

    Article  CAS  PubMed  Google Scholar 

  8. Jiang M et al (2016) SHP1 regulates bone mass by directing mesenchymal stem cell differentiation. Cell Rep 17(8):2161

    Article  CAS  PubMed  Google Scholar 

  9. Markovics A et al (2020) Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase. Arthritis Res Ther 22(1):160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bouxsein ML et al (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468–1486

    Article  PubMed  Google Scholar 

  11. Bhatia A et al (2012) Overexpression of DMP1 accelerates mineralization and alters cortical bone biomechanical properties in vivo. J Mech Behav Biomed Mater 5(1):1–8

    Article  CAS  PubMed  Google Scholar 

  12. Coggeshall KM, Nakamura K, Phee H (2002) How do inhibitory phosphatases work? Mol Immunol 39(9):521–529

    Article  CAS  PubMed  Google Scholar 

  13. Martin A et al (1999) Murine SHP-1 splice variants with altered Src homology 2 (SH2) domains. Implications for the SH2-mediated intramolecular regulation of SHP-1. J Biol Chem 274(31):21725–21734

    Article  CAS  PubMed  Google Scholar 

  14. Raab M, Rudd CE (1996) Hematopoietic cell phosphatase (HCP) regulates p56LCK phosphorylation and ZAP-70 binding to T cell receptor zeta chain. Biochem Biophys Res Commun 222(1):50–57

    Article  CAS  PubMed  Google Scholar 

  15. Chiang GG, Sefton BM (2001) Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase. J Biol Chem 276(25):23173–23178

    Article  CAS  PubMed  Google Scholar 

  16. Au-Yeung BB et al (2009) The structure, regulation, and function of ZAP-70. Immunol Rev 228(1):41–57

    Article  CAS  PubMed  Google Scholar 

  17. Nishizumi H et al (1998) A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signals. J Exp Med 187(8):1343–1348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Xu Y et al (2005) Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 22(1):9–18

    PubMed  Google Scholar 

  19. Dustin LB et al (1999) Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation. J Immunol 162(5):2717–2724

    Article  CAS  PubMed  Google Scholar 

  20. Qin C, Baba O, Butler WT (2004) Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15(3):126–136

    Article  CAS  PubMed  Google Scholar 

  21. Staines KA, MacRae VE, Farquharson C (2012) The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214(3):241–255

    Article  CAS  PubMed  Google Scholar 

  22. Yang H et al (2022) Protein tyrosine phosphatases in skeletal development and diseases. Bone Res 10(1):10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Huang TT et al (2017) Alteration of SHP-1/p-STAT3 signaling: a potential target for anticancer therapy. Int J Mol Sci 18:6

    Article  Google Scholar 

  24. Hou X, Tian F (2022) STAT3-mediated osteogenesis and osteoclastogenesis in osteoporosis. Cell Commun Signal 20(1):112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Yang Y et al (2019) STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription. J Biol Chem 294(42):15395–15407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Davidson RK et al (2020) The loss of STAT3 in mature osteoclasts has detrimental effects on bone structure. PLoS ONE 15(7):e0236891

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Follet H et al (2004) The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone 34(5):783–789

    Article  CAS  PubMed  Google Scholar 

  28. Boskey AL et al (2010) MEPE’s diverse effects on mineralization. Calcif Tissue Int 86(1):42–46

    Article  CAS  PubMed  Google Scholar 

  29. Liu H, Xia X, Li B (2015) Mesenchymal stem cell aging: mechanisms and influences on skeletal and non-skeletal tissues. Exp Biol Med (Maywood) 240(8):1099–1106

    Article  CAS  PubMed  Google Scholar 

  30. Yuko Takeda-Matsubara HN, Iwai M, Cui TX, Shiuchi T, Masahiro Akishita CN, Ito M, Horiuchi M (2002) Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension 39:41–45

    Article  PubMed  Google Scholar 

  31. Ke K et al (2014) Reactive oxygen species induce the association of SHP-1 with c-Src and the oxidation of both to enhance osteoclast survival. Am J Physiol Endocrinol Metab 307(1):E61-70

    Article  CAS  PubMed  Google Scholar 

  32. Xu D, Rovira II, Finkel T (2002) Oxidants painting the cysteine chapel: redox regulation of PTPs. Dev Cell 2(3):251–2

    Article  CAS  PubMed  Google Scholar 

  33. Bell MR (2018) Comparing postnatal development of gonadal hormones and associated social behaviors in rats, mice, and humans. Endocrinology 159(7):2596–2613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors express their gratitude to Dr. Tibor T. Glant for providing founders of the SHP1-Tg mouse strain. No funding was received to conduct this study.

Author information

Authors and Affiliations

Authors

Contributions

Study conception and design were provided by DRS, RDR, AM, and KM. Material preparation, data collection, and analysis were performed by AM, RDR, SL, and NP. The first draft of the manuscript was written by AM. Editing and critical review of previous versions of the manuscript were performed by RDR, DRS, and KM. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Adrienn Markovics.

Ethics declarations

Disclosure

Adrienn Markovics, Sydney Lupo, Niyati Patel, Katalin Mikecz, D. Rick Sumner, and Ryan D. Ross have no relevant financial or non-financial interest to disclose.

Ethical Approval

All animal protocols were approved by the Institutional Animal Care and Use Committee (Rush University, Chicago, IL, IACUC 17–039).

Consent for Publications

All authors approve the manuscript for publication in its present form.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markovics, A., Lupo, S., Patel, N. et al. SHP-1 Protein Tyrosine Phosphatase Affects Early Postnatal Bone Development in Mice. Calcif Tissue Int 112, 472–482 (2023). https://doi.org/10.1007/s00223-023-01064-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-023-01064-5

Keywords

Navigation